CD371 Mouse anti-Human, BB515, Clone: 50C1, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 565325
The 50C1 monoclonal antibody specifically binds to human CD371 which is also known as, Clec12A (C-type lectin domain family 12 member A), C-type lectin-like molecule 1 (CLL-1), myeloid inhibitory C-type lectin-like receptor (MICL), or dendritic cell-associated lectin 2 (DCAL-2). It is expressed on a variety of cells including monocytes, macrophages, dendritic cells, and granulocytes and perhaps some NK cells. Cleck12A is a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. It is a 30 kDa type II transmembrane glycoprotein that has one single C-type lectin-like domain and one cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM). Clec12A has similarity with the β-glucan receptor (Dectin-1) and LOX-1 with high N-glycosyla tion. There are at least five isoforms due to alternative transcript splicing. Signaling through Clec12A can induce internalization of Cleck12A, dendritic cell maturation and the production of cytokines including IL-12. Clec12A may also serve as a negative regulator of activated leukocytes recruited to sites of inflammation.
The antibody was conjugated to BD Horizon BB515 which was developed exclusively by BD Biosciences. With an excitation max of 490nm and an emission max of 515nm, BD Horizon BB515 can be excited by the 488nm laser and detected in a standard FITC set (eg, 530/30-nm filter). This dye provides a much brighter alternative to FITC with less spillover into the PE detector.
|CD371; Clec12A; MICL; CLL-1; DCAL-2|
|Human CLEC12A Transfected Cell Line|
|Aqueous buffered solution containing ≤0.09% sodium azide.|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok